Little Hiccup Costs Affy $10M-$12M in Q3; ParAllele Acquisition Delayed to Q4 | GenomeWeb

Affymetrix said last week that technical issues with the manufacturing process of its 500K GeneChips have caused third-quarter revenues to be around 13 percent shy of earlier expectations, and warned that while it claims to have rectified the problems, it will "be careful about claiming that anything is resolved."

The company also said that it has postponed its acquisition of ParAllele Biosciences, which will now close in the fourth quarter rather than the third quarter.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.